Browse the evidence

GLP-1 receptor agonist medications have the potential to promote marked weight loss.

Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.

Obesity should be framed as a chronic, multifactorial disease requiring comprehensive management strategies.

A multidisciplinary approach is essential for effective obesity management.

Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.

Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.

Current data indicate a rapid shift from single-pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes.

Practitioners should consider multimodal approaches as the future direction for treating obesity and type 2 diabetes.

The DRL agent achieved a prediction accuracy of optimal doses of 92%, exceeding traditional models by 15%.

The DRL agent can provide more accurate dosing recommendations compared to traditional methods.

In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia.

Retatrutide may improve glycemic control in patients with type 2 diabetes.

An unhealthy lifestyle increases the risk of developing type 2 diabetes more significantly in women than in men.

Healthcare providers should emphasize lifestyle changes, particularly for women, to reduce diabetes risk.

The guidelines focus on cardiovascular risk stratification and management of cardiovascular risk factors in diabetes.

Focus on cardiovascular risk factors is essential for diabetes management.

Quality of life, as measured by the Short Form-36 (SF-36), improved in the experimental group.

Improving quality of life is an important benefit of structured exercise for diabetic patients.

Insulin resistance compromises the body's normal response to insulin, leading to multiple diseases including Type 2 diabetes mellitus.

Practitioners should recognize insulin resistance as a critical factor in managing metabolic diseases.

Physical activity may counteract the aging-related decline in bone mass but does not strongly attenuate menopause-related bone loss in women.

Consider pharmacologic therapy for postmenopausal women to prevent bone loss, even if active.

Ramipril is associated with lower rates of new diagnosis of diabetes in high-risk individuals, with 3.6% in the ramipril group developing diabetes compared to 5.4% in the placebo group (RR, 0.66; P<.001).

Practitioners may consider ramipril as a preventive strategy for diabetes in high-risk patients.

Ramipril also showed a relative risk of 0.56 for the initiation of glucose-lowering therapy.

This indicates that ramipril may reduce the need for glucose-lowering medications in high-risk patients.

Abdominal obesity is related to an increased likelihood of undergoing prostatectomy for benign prostatic hyperplasia (OR = 2.38, 95% CI 1.42-3.99) for men with a waist circumference ≥ 43 inches compared to those with a waist circumference < 35 inches.

Practitioners should consider abdominal obesity as a significant risk factor for benign prostatic hyperplasia and potential surgical intervention.

The parasympathetic, Addison type, overtraining syndrome is characterized by an autonomic or neuroendocrine imbalance.

Practitioners should consider autonomic imbalances when assessing athletes for overtraining syndrome.

CHO ingestion blunted the increase in plasma IL-6 concentration during exercise (P < 0.01).

Ingesting carbohydrates during exercise can help reduce inflammatory responses.

A new approach via personalized therapy adaptations must be applied to target beneficial effects on complications as well as on body weight management.

Tailoring exercise and nutrition strategies can improve health outcomes for individuals with type 1 diabetes.

Human chorionic gonadotropin (HCG) is effective in treating male infertility due to its luteinizing hormone-like action that triggers testosterone and sperm production.

HCG may be a preferable treatment option for male infertility compared to testosterone replacement therapy.

HCG therapy has positive effects on testosterone production without the side effects on fertility associated with testosterone replacement therapy.

HCG therapy may be recommended for patients concerned about fertility while needing testosterone treatment.

Important parameters for choosing glucose-lowering agents include drug efficacy, risk of hypoglycemia, effect on weight, side effects, and cost.

Practitioners should evaluate these parameters when selecting glucose-lowering agents.

In cancer survivors with obesity, metformin treatment resulted in a significant decrease in IGF-1 levels by 7.2 ng/mL at 6 months.

Metformin may be considered as a treatment option for reducing IGF-1 levels in obese cancer survivors.

New medications for T2DM, such as semaglutide, tirzepatide, and ertugliflozin, have been recently approved.

Healthcare providers should stay informed about newly approved medications for T2DM management.

Post-RYGB patients were more prone to eat on external cues compared to controls (13 ± 7 vs. 19 ± 13; p = 0.007).

Practitioners should be aware that post-surgery patients may need support in managing external eating cues.

Gastroenterologists can play an important role in the management of obesity.

Gastroenterologists should be prepared to manage obesity in their patients.